Sanofi (SNY) to Acquire Provention Bio (PRVB) for $25 a Share. Gains 243%.
Up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of hard partying at the C-3.
How pray tell,...
Meet Dennis Nguyen CEO of Start-Up Investor, the Society Pass (Symbol: SOPA)
See a Dazzling Presentation!
Society Pass (SOPA) has quickly acquired 8 companies since going public in late 2021, after a $26 million IPO on...
Silo Pharma (SILO) $2.25, Now Our Favorite Psychedelic.
We Liked it at $3.50, we Love it at $2.25.
Down but not out. Now trading below the cash they have in the bank, this...
Institutional Analyst: Our #1 Internet Company, Society Pass (Nasdaq: SOPA), Holds Appeal for Both...
Press Release:
February 28, 2023 07:30 ET | Source: Society Pass Incorporated
New York, NY, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Institutional Analyst Inc (“Institutional Analyst”) issues...
New Report: Society Pass (SOPA), Our #1 Internet Company Trading Under $5.00.
Our #1 Internet Company Trading Under $5.00, Society Pass Holds Appeal for Both Traders and Long-Term Investors.
“While the Internet Stock Review is geared for...
Dennis Nguyen, Founder/Chairman/CEO of Nasdaq-listed Society Pass Inc. (Nasdaq: SOPA) to Speak at NXT...
SINGAPORE, Feb. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Society Pass Incorporated ("SoPa”) ( Nasdaq: SOPA ), Southeast Asia’s (SEA) next generation, data-driven, loyalty, fintech and e-commerce ecosystem, today...
Adding Principal Solar (PSWW) to Watch List.
LIVE QUOTE
Principal Solar Website
And we found another Incubator! This one acquiring stakes in technologies that support next-generation opportunities in traditional, renewable, and clean energy...
Revive Therapeutics (RVVTF) Advancing MDMA Thermal Patch.
Two News Reports Related to Revives Upcoming Microneedle Patch Technology
While we are still laser focused on Revive having a successful meeting with the FDA...
SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53% Intraday on Patent (Ketamine) Related News
Our opinion...
Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Uptick in patient recruitment for Mino-Lok® Phase 3 trial
Halo-Lido Phase 2b trial nearing completion
CRANFORD,...















